Zijuan Zhang, Ming Shi, Zhengmin Li, Yuan Ling, Luke Zhai, Ye Yuan, He Ma, Li Hao, Zhonghua Li, Zhenqiang Zhang, Christian Hölscher
Parkinson's disease (PD) is a complex syndrome with many elements, such as chronic inflammation, oxidative stress, mitochondrial dysfunction, loss of dopaminergic neurons, build-up of alpha-synuclein ( α -syn) in cells, and energy depletion in neurons, that drive the disease. We and others have shown that treatment with mimetics of the growth factor glucagon-like peptide 1 (GLP-1) can normalize energy utilization, neuronal survival, and dopamine levels and reduce inflammation. Liraglutide is a GLP-1 analogue that recently showed protective effects in phase 2 clinical trials in PD patients and in Alzheimer disease patients...
2023: Parkinson's Disease